Johnson & Johnson will "exit the opioid business domestically" in the United States under a $ 230 million settlement with New York, state attorney general Letitia James said Saturday.
The settlement allows Johnson & Johnson to settle litigation over its role in "fueling the opioid epidemic," according to a statement from the prosecution, which said the company will spread the payments over nine years.
The pharmaceutical company is one of the largest suppliers of the raw materials used to produce opioid pain relievers such as fentanyl or oxycodone, opioid synthetic narcotics used to cushion severe pain in cancer patients.
Since 2017, the company has faced lawsuits in the United States for accusations of contributing to addictions with these drugs, one of them in Washington.
Johnson & Johnson increased its net income 6.9% in the first quarter of 2021 to 6,197 million dollars. Revenues were strong in the segment of medical devices, where they increased 10.9% year-on-year to 6,579 million, and in the division pharmaceutical company, which reported a revenue increase of 9.6% to $ 12.199 million
With information from AFP.
